A nasal mucosa vaccine model utilizing an adenoviral vector encoding tumor-associated antigens demonstrated that both prophylactic and therapeutic applications significantly increased the number of CD8+ TRMs in lung tissue. The gene discussed is CD8A; the disease is neoplasm.